- Home
- PRPO vs CLRB Comparison
PRPO vs CLRB Comparison
Compare PRPO & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- CLRB
- Stock Information
- Founded
- PRPO N/A
- CLRB 2002
- Country
- PRPO United States
- CLRB United States
- Employees
- PRPO N/A
- CLRB N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- CLRB Health Care
- Exchange
- PRPO Nasdaq
- CLRB Nasdaq
- Market Cap
- PRPO 17.1M
- CLRB 17.6M
- IPO Year
- PRPO N/A
- CLRB N/A
- Fundamental
- Price
- PRPO $14.45
- CLRB $4.78
- Analyst Decision
- PRPO
- CLRB Hold
- Analyst Count
- PRPO 0
- CLRB 2
- Target Price
- PRPO N/A
- CLRB N/A
- AVG Volume (30 Days)
- PRPO 17.7K
- CLRB 166.2K
- Earning Date
- PRPO 08-12-2025
- CLRB 08-12-2025
- Dividend Yield
- PRPO N/A
- CLRB N/A
- EPS Growth
- PRPO N/A
- CLRB N/A
- EPS
- PRPO N/A
- CLRB N/A
- Revenue
- PRPO $20,029,000.00
- CLRB N/A
- Revenue This Year
- PRPO N/A
- CLRB N/A
- Revenue Next Year
- PRPO N/A
- CLRB N/A
- P/E Ratio
- PRPO N/A
- CLRB N/A
- Revenue Growth
- PRPO 26.67
- CLRB N/A
- 52 Week Low
- PRPO $3.90
- CLRB $4.36
- 52 Week High
- PRPO $16.89
- CLRB $94.50
- Technical
- Relative Strength Index (RSI)
- PRPO 68.17
- CLRB 33.97
- Support Level
- PRPO $14.25
- CLRB $4.62
- Resistance Level
- PRPO $16.89
- CLRB $5.17
- Average True Range (ATR)
- PRPO 1.08
- CLRB 0.74
- MACD
- PRPO 0.24
- CLRB -0.19
- Stochastic Oscillator
- PRPO 67.57
- CLRB 7.20
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.